|By PR Newswire||
|March 12, 2014 07:00 AM EDT||
GENEVA, March 12, 2014 /PRNewswire/ --
Novimmune S.A announced today that Andrew J. Oakley has joined the company as Chief Financial Officer.
Andrew Oakley, an Australian national, who most recently served as the CFO of Swiss-based Actelion Ltd, is also joining Novimmune's Executive Committee. His appointment is effective immediately.
In announcing the appointment, Jack Barbut, Chief Executive Officer of Novimmune, commented: "I am very pleased to welcome Andrew to Novimmune. With Novimmune's research and development efforts maturing, our company will benefit significantly from his extensive experience in both the bio-pharmaceutical industry and the global capital markets."
Dr. Eduard Holdener, Chairman of Novimmune, added, "We are delighted that Novimmune has been able to attract a professional of such high caliber as Andrew. The appointment of such an experienced public company CFO highlights our ambition to rapidly advance Novimmune's corporate and business strategy."
In his ten years at Actelion, a global bio-pharmaceutical company with a market capitalization exceeding CHF 10 billion, Andrew built and led a global finance function and initiated and executed a number of Capital Markets Transactions. Prior to this appointment, Andrew held a number of senior managerial and financial roles at several organizations in Australia, the UK and the US.
Andrew J. Oakley said, "I am excited to join my new colleagues at Novimmune at this important time in the Company's development. I am confident that together, we will continue to create value for our investors, and benefits for patients, by advancing important new medicines either through strategic collaborations or, in the case of orphan indications, on our own."
Novimmune SA is a privately-held drug discovery and development company focused on the creation of antibody-based drugs to treat patients with inflammatory diseases, auto-immune disorders, and cancer. To date, the company has a pipeline that consists of a balance of preclinical and clinical candidates for validated and novel targets. In addition, Novimmune has created a proprietary, next-generation drug discovery platform that includes the ability to generate unique and proprietary bi-specific antibodies.
The company also plans to soon bring targeted medicines to market for selected orphan drug applications.
Dec. 8, 2016 09:45 PM EST Reads: 1,233
Dec. 8, 2016 09:15 PM EST Reads: 1,665
Dec. 8, 2016 09:15 PM EST Reads: 947
Dec. 8, 2016 08:30 PM EST Reads: 1,883
Dec. 8, 2016 07:45 PM EST Reads: 313
Dec. 8, 2016 07:15 PM EST Reads: 374
Dec. 8, 2016 06:45 PM EST Reads: 949
Dec. 8, 2016 05:45 PM EST Reads: 947
Dec. 8, 2016 05:45 PM EST Reads: 1,719
Dec. 8, 2016 05:00 PM EST Reads: 1,817
Dec. 8, 2016 04:45 PM EST Reads: 1,846
Dec. 8, 2016 04:45 PM EST Reads: 2,251
Dec. 8, 2016 04:30 PM EST Reads: 388
Dec. 8, 2016 04:30 PM EST Reads: 1,972
Dec. 8, 2016 04:15 PM EST Reads: 310